Jeil Pharmaceutical Selected for K-VIP Program: "Expanding Global Business Development"

Supporting Overseas Partnering Activities of Domestic Companies

Jeil Pharmaceutical announced on the 6th that it has been selected as a participating company in the '2026 2nd Global Pharmaceutical and Biotech Overseas Expansion Support Program (K-VIP)' for the global conference, exhibition, and partnering event support sector, which is organized by the Korea Health Industry Development Institute (KHIDI).

K-VIP is a government program established to support the sustainable global expansion of domestic pharmaceutical and biotech companies. It aims to systematically strengthen the global competitiveness and market entry capabilities of the domestic pharmaceutical and biotech industry by supporting companies in response to stronger export/import regulations, supply chain risks, and changes in international trade environments worldwide.

Jeil Pharmaceutical provides financial support to domestic pharmaceutical and biotech companies seeking to enter global markets, specifically for their participation in overseas events.

Jeil Pharmaceutical plans to utilize this support program to participate in major global partnering events such as Bio-Europe 2026. Through on-site partnering meetings with global pharmaceutical and biotech companies, the company aims to expand opportunities for potential partnerships and explore various possibilities for business collaboration.

Sumi Kim, Head of Global Business Division at Jeil Pharmaceutical, stated, "While we continue to expand the global commercialization of Jakubo, we will also strive to broaden opportunities for our proprietary new drug pipeline to enter overseas markets and to translate them into tangible results."

This content was produced with the assistance of AI translation services.